| Primary | Part A: Percentage of Participants Achieving a ≥ 50% Improvement in SALT50 Response in Terminal Hair (Pigmented and Nonpigmented). | Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss. | Part A evaluable population in treatment period includes all subjects exposed to at least 1 dose of study drug in that period. | Posted | | Count of Participants | | Participants | | Up to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A: Ruxolitinib Cream | Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks |
| | | Title | Denominators | Categories |
|---|
| Week 4 | | | | Week 8 | | | | Week 12 | | |
| |
| Primary | Part B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented) | Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss. | Intent to Treat population in the Part B treatment period i.e all participants who are randomized | Posted | | Count of Participants | | Participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part B : Placebo Cream | Part B: Double-blind treatment is 24 weeks and/or optional treatment with Ruxolitinib Phosphate Cream if eligible and follow-up is an additional 12 weeks | | OG001 | Part B: Ruxolitinib Cream | Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks. |
| |
| Secondary | Part A : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair. | Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes. | The subgroup analysis was performed on subjects exposed to at least 1 dose of study drug in that period with a baseline SALT score of 50-100%. | Posted | | Count of Participants | | Participants | | Up to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A: Ruxolitinib Cream | Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks |
| |
| Secondary | Part B : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented). | Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes. | The subgroup analysis was performed on subjects exposed to at least 1 dose of study drug in that period with a baseline SALT score of 50-100%. | Posted | | Count of Participants | | Participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part B : Placebo Cream | Part B: Double-blind treatment is 24 weeks and/or optional treatment with Ruxolitinib Phosphate Cream if eligible and follow-up is an additional 12 weeks | | OG001 | Part B : Ruxolitinib Cream | Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks. |
| |
| Secondary | Part A and B : Percentage of Participants Achieving a SALT90 Response in Terminal Hair. | Number of participants achieving 90% or greater improvement in their SALT score (SALT90) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes. | Part A evaluable population in treatment period includes all subjects exposed to at least 1 dose of study drug in that period. Intent to Treat population in the Part B treatment period i.e all participants who are randomized. | Posted | | Count of Participants | | Participants | | Weeks 4, 8, 12, 18, and 24. | | | | ID | Title | Description |
|---|
| OG000 | Part A: Ruxolitinib Cream | Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks | | OG001 | Part B : Placebo Cream | Part B: Double-blind treatment is 24 weeks and/or optional treatment with Ruxolitinib Phosphate Cream if eligible and follow-up is an additional 12 weeks. | | OG002 | Part B : Ruxolitinib Cream | Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks. |
|
| Secondary | Part B : Percentage of Subjects Whose AA Lesions Treated Since Baseline Achieved a Physician's Global Assessment of Regrowth (PGARG) Score of at Least 3 | Number of subjects achieving a Physician's Global Assessment (PGA) score of 3 or above at week 24 (0, no regrowth; 1, <25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth). | Intent to Treat population in the Part B treatment period i.e all participants who are randomized. Participants dropped out of study by week 24 were excluded from analysis. | Posted | | Count of Participants | | Participants | | Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part B : Placebo Cream | Part B: Double-blind treatment is 24 weeks and/or optional treatment with Ruxolitinib Phosphate Cream if eligible and follow-up is an additional 12 weeks. | | OG001 | Part B : Ruxolitinib Cream | Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks. |
| |
| Secondary | Part B : Percentage of Participants Achieving a SALT50 in Terminal Hair (Pigmented and Nonpigmented). | Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes | Intent to Treat population in the Part B treatment period i.e all participants who are randomized. | Posted | | Count of Participants | | Participants | | Weeks 4, 8, 12, and 18. | | | | ID | Title | Description |
|---|
| OG000 | Part B : Placebo Cream | Part B: Double-blind treatment is 24 weeks and/or optional treatment with Ruxolitinib Phosphate Cream if eligible and follow-up is an additional 12 weeks. | | OG001 | Part B : Ruxolitinib Cream | Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks. |
| |
| Secondary | Part B: Mean Change From Baseline in SALT Score | Severity of Alopecia Tool Score (SALT) calculation is based on a scoring system. The scalp is divided into the following 4 areas: 1) Vertex: 40% (0.4) of scalp surface area, 2) Right profile of scalp: 18% (0.18) of scalp surface area, 3) Left profile of scalp: 18% (0.18) of scalp surface area, and 4) Posterior aspect of scalp: 24% (0.24) of scalp surface area. The percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area. The SALT score is the sum of percentage of hair loss in all the above-mentioned areas, so a lower number indicates a better outcome. The reported SALT score range is from a minimum of 0 (no hair loss) to a maximum of 100 (100% hair loss). | Intent to Treat population in the Part B treatment period i.e all participants who are randomized. | Posted | | Least Squares Mean | Standard Error | Units on a Scale | | Weeks 4, 8, 12, 18, and 24. | | | | ID | Title | Description |
|---|
| OG000 | Part B : Placebo Cream | Part B: Double-blind treatment is 24 weeks and/or optional treatment with Ruxolitinib Phosphate Cream if eligible and follow-up is an additional 12 weeks. | | OG001 | Part B : Ruxolitinib Cream | Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks. |
| |
| Secondary | Part A and B : Number of Treatment-emergent Adverse Events | Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment | All enrolled subjects who received at least 1 dose of INCB018424 or Placebo. | Posted | | Count of Participants | | Participants | | Up to 100 weeks | | | | ID | Title | Description |
|---|
| OG000 | Part A: Ruxolitinib Cream | Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks | | OG001 | Part B : Placebo Cream | Part B: Double-blind treatment is 24 weeks and/or optional treatment with Ruxolitinib Phosphate Cream if eligible and follow-up is an additional 12 weeks. | | OG002 | Part B : Ruxolitinib Cream | Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks. |
| |